Thought Leadership

Robust Data Forecasts in the changing healthcare environment

On August 24, 2015, Tags
What’s the issue? The healthcare environment today is not what it used to be. Over the past several decades many pharmaceutical companies have primarily focused on main stream diseases affecting larger populations with unmet clinical needs and limited treatment options. Pharma companies set their sights on discovering blockbuster drugs to address a medical problem for…

Understanding the ‘big picture’

On July 17, 2015, In Director Articles, Tags
In this article, Nic Talbot-Watt, Director of Analysis and Forecasting at Black Swan Analysis, highlights the advantage of having a robust commercial understanding of their healthcare innovation early in the development process and the challenges and disappointment when you get it wrong. The most exciting part of delivering some form of innovation in the healthcare…

Can rare diseases be a viable option for the pharma industry?

In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US since the Orphan Drug Act of 1983 and the factors driving pharma to invest its research and development budgets into discovering orphan drugs.   Background Rare…

Defining patient populations is a key trend shaping the pharma industry

Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the future, the industry needs to have a better understanding of the patient populations for each individual disease. (Continued from “Enablers of drug innovation…

Enablers of drug innovation could lie in the numbers

Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem. Recent developments in the pharmaceutical industry are encouraging drug developers to re-think their strategies toward innovation and development. The expiration of blockbuster patents and the subsequent…